GRN-529

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
GRN-529
GRN-529.svg
Systematic (IUPAC) name
(4-(Difluoromethoxy)-3-(pyridin-2-ylethynyl)phenyl)(5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)methanone
Identifiers
CAS Number 1253291-12-1
IUPHAR/BPS 6428
ChemSpider 27471591
Chemical data
Formula C22H15F2N3O2
Molecular mass 391.11 g/mol
  • O=C(N1CC(C=CC=N2)=C2C1)C3=CC(C#CC4=CC=CC=N4)=C(OC(F)F)C=C3
  • InChI=1S/C22H15F2N3O2/c23-22(24)29-20-9-7-16(12-15(20)6-8-18-5-1-2-10-25-18)21(28)27-13-17-4-3-11-26-19(17)14-27/h1-5,7,9-12,22H,13-14H2
  • Key:JITMSIRHBAVREW-UHFFFAOYSA-N

GRN-529 is a research drug that was developed by Wyeth as a negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5).[1]

A study conducted by Pfizer found that GRN-529 reduced repetitive behaviors without sedation and partially increased sociability in mouse models of autism. [2]

Another study conducted by Pfizer found a therapeutically relevant effect in animal models of depression. It is theorized to work by reducing glutamate receptor hyperactivity.[3]

See also

References

  1. ↑ US Patent Application No. 20100273772 Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.



<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=GRN-529&oldid=713205242"